Stalled TPP Gives Generics More Time To Push Back
This article was originally published in PharmAsia News
Generic drug makers and others who oppose certain portions of the Trans-Pacific Partnership free-trade deal will have more time to try to convince negotiators and ministers to change course after the 12 nations involved failed to reach an agreement at what the USTR had hoped would be the final meeting in Hawaii.
You may also be interested in...
From efficacy endpoints to patient warehousing, US FDA advisors weigh in on vaccine development and regulatory review.
Several years ago, heart device giant Edwards Lifesciences realized it needed a new CAPA framework that shifts corrective and preventive action from a one-size-fits-all method to a more nuanced approach. See what Dan Buehner, director of quality engineering at Edwards Lifesciences, said about it here.
FDA's recommendation that COVID-19 vaccine sponsors conduct two months of median follow-up to support an emergency use authorization may not be long enough, some experts say in what can be viewed as validation for agency's position in battle with White House.